Organization
Shandong New Time Pharmaceutical
8 clinical trials
Clinical trial
An Open, Single-arm, Multicenter Phase II Trial of Efficacy and Safety of F520 Monotherapy in the Treatment of Advanced, Persistent, Recurrent, or Metastatic Cervical CancerStatus: Completed, Estimated PCD: 2023-12-05
Clinical trial
A Placebo Control, Randomized, Double-blind, Multicenter Phase IV Study to Investigate the Efficacy and Safety of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver (Damp-heat Obstruction Syndrome: Shi-Re-Zhong-Zu Zheng)Status: Completed, Estimated PCD: 2018-11-08
Clinical trial
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Initial Efficacy of LNF1901 in Advanced Malignant TumorsStatus: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of XZ120 in Patients With Malignant Tumors in a Phase Ⅰ Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Single-arm, Multicenter Phase IV Study to Investigate the Efficacy and Safety of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver (Damp-heat Obstruction Syndrome: Shi-Re-Zhong-Zu Zheng)Status: Completed, Estimated PCD: 2022-06-09
Clinical trial
A Single-arm, Open-label, and Multicenter Phase Ⅱ Study Designed to Evaluate the Efficacy and Safety of Rulonilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Status: Not yet recruiting, Estimated PCD: 2024-10-25
Clinical trial
Phase Ⅱ/III Studies to Investigate the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Multicenter, Open-label, Phase Ib/II Study on the Efficacy and Safety of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-05-22